Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 561Leukemia 282Precursor Cell Lymphoblastic Leukemia-Lymphoma 235Myelodysplastic Syndromes 110Congenital Abnormalities 86Leukemia, Monocytic, Acute 84Leukemia, Myelomonocytic, Acute 82Leukemia, Erythroblastic, Acute 75Leukemia, Megakaryoblastic, Acute 72Lymphoma 65Burkitt Lymphoma 62Recurrence 61Leukemia, Myelomonocytic, Chronic 43Leukemia, Biphenotypic, Acute 43Lymphoma, Non-Hodgkin 41Blast Crisis 37Anemia, Refractory, with Excess of Blasts 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 35Leukemia, Lymphocytic, Chronic, B-Cell 33Lymphoma, Large B-Cell, Diffuse 30Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 28Myeloproliferative Disorders 27Lymphoma, Follicular 27Lymphoma, Large-Cell, Immunoblastic 25Lymphoma, Mantle-Cell 24Leukemia, Myeloid, Chronic-Phase 23Leukemia, Eosinophilic, Acute 23Hodgkin Disease 23Lymphoma, B-Cell, Marginal Zone 22Leukemia, Basophilic, Acute 22

Interventions

fludarabine phosphate 2Whole-Body Irradiation 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Cyclosporine 2ruxolitinib 1merphos 1Tacrolimus 1Observation 1Methotrexate 1MK 2206 1In Situ Hybridization, Fluorescence 1Flow Cytometry 1Cytogenetic Analysis 1Cytarabine 1Cyclophosphamide 1Busulfan 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Syndrome, Transient × Cytarabine × Other hematologic neoplasm × Clear all
NCT00411281 2015-09-30

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Children's Oncology Group

Phase 3 Withdrawn
MyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡